Neither of these interventions are disease modifying, whereas the multifaceted effects of CNP described herein suggest that pharmacological delivery of the peptide can reverse portal hypertension while simultaneously targeting the underlying pathogenesis. This evidence concerns the gene CNP and liver disorder.